Omeprazole: A Comprehensive Review

Firouzan Massoomi, John Savage, Christopher J. Destache

Research output: Contribution to journalReview article

66 Scopus citations


Omeprazole is a member of a new class of substituted benzimidazoles. These agents inhibit the proton pump in the gastric parietal cell, blocking the final step in the gastric acid secretory pathway. Omeprazole has been investigated for the treatment of gastric ulcer, duodenal ulcer, gastroesophageal reflux, and various hypersecretory states. The prolonged inhibition of gastric acid secretion allows for once-daily dosing in patients with peptic ulcer disease and gastroesophageal reflux, and once- or twice- daily dosing in patients with Zollinger-Ellison syndrome. Compared with currently available therapies, omeprazole is well tolerated and demonstrates a more rapid ulcer healing rate. It is superior to conventional therapies in the treatment of Zollinger-Ellison syndrome. Side effects are infrequent when the drug is used for the short-term management of ulcers.

Original languageEnglish (US)
Pages (from-to)46-59
Number of pages14
JournalPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Issue number1
StatePublished - Jan 1 1993

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Omeprazole: A Comprehensive Review'. Together they form a unique fingerprint.

  • Cite this